United States · Compounding pharmacy · Compounded

Empower Pharmacy review

The supply side rather than the sales side — a 503A compounding pharmacy that publishes exact vial concentrations and will not sell to you directly.

Reviewed 2026-08-157/13 checklist items publishedProvider site ↗

Overview

Empower is not a telehealth service and does not want your business directly: “this compounded injection is available exclusively through our 503A compounding pharmacy pursuant to a patient-specific prescription.” It is included here because it answers a question none of the telehealth services selling compounded GLP-1s will — what is actually in the vial.

Its tirzepatide product is formulated with niacinamide and published at specific concentrations: 17/2 mg/mL and 8/2 mg/mL, in 2 mL, 2.5 mL and 4 mL vials. That is precisely the detail our own compounded-GLP-1 guide tells readers to ask for, and it is rare to see it published anywhere.

The regulatory disclosure is unambiguous: “Compounded medications are not FDA-approved medications, and FDA does not review compounded medications for safety or efficacy.” The 503A designation matters too — a 503A facility compounds against a patient-specific prescription, rather than producing in bulk the way a 503B outsourcing facility does.

Medications and supply

Compounded at a 503A facility, dispensed only against a patient-specific prescription. Empower states compounded medications are not FDA-approved and that FDA does not review them for safety or efficacy.

  • Compounded tirzepatide / niacinamide injection

How the service works

Consultation
None. Empower does not prescribe — a prescription must come from your own healthcare provider.
Eligibility
A valid patient-specific prescription from a healthcare provider is required.
Provider involvement
None. This is a dispensing pharmacy, not a clinical service.
Lab requirements
Not stated in the sources we checked.
Pharmacy fulfilment
Its own 503A compounding facility, dispensing against patient-specific prescriptions.
Shipping
Not stated in the sources we checked.
Support services
Not stated in the sources we checked.

What it costs

Published prices for Empower Pharmacy
ItemPublished priceNotes
Tirzepatide / niacinamide injectionnot published17/2 mg/mL and 8/2 mg/mL, in 2 mL, 2.5 mL and 4 mL vials
Membership fee
None — there is no subscription.
Medication fee
Not published on the product page.
Insurance
Not stated in the sources we checked.
HSA / FSA
Not stated in the sources we checked.
Cancellation
Not applicable — there is no recurring plan.
Refunds
Not stated in the sources we checked.

Pros

  • Publishes exact vial concentrations, which almost no compounded seller does
  • States the 503A designation openly, so you know which regime it operates under
  • Unambiguous FDA disclosure on the product page itself
  • Requires a patient-specific prescription rather than selling direct

Cons

  • No price published
  • Not a route in on its own — you need a prescriber first
  • The niacinamide combination is a formulation choice with no trial data behind it
  • Nothing published on shipping, storage handling or returns

Who it may suit

Someone who already has a compounded prescription and wants to know exactly what their pharmacy is dispensing — or a prescriber choosing a compounder.

Limitations

  • Compounded products are not FDA-approved, as Empower states directly
  • Combination formulations like tirzepatide with niacinamide have not been through the trials the single-molecule products have

Questions

Can I buy from Empower directly?

No. It states the product is available exclusively through its 503A pharmacy pursuant to a patient-specific prescription, which has to come from your own healthcare provider.

What is the difference between 503A and 503B?

Broadly, a 503A pharmacy compounds against an individual patient-specific prescription, while a 503B outsourcing facility can produce in bulk without one. Empower states this product comes from its 503A facility.

Why does the tirzepatide have niacinamide in it?

It is a formulation choice by the compounder. Note that the combination has not been through the trials the single-molecule approved products have — the published trial results on this site do not transfer to it.

Sources

Everything on this page traces to one of the links below, retrieved on the date shown. Prices and programme terms in this market change without notice — confirm against the provider before you buy.

  1. 01Empower Pharmacy — tirzepatide/niacinamide injection (503A status, concentrations, FDA disclosure)retrieved 2026-08-15